PPMX T004
Alternative Names: PPMX-T004Latest Information Update: 25 Aug 2023
At a glance
- Originator Perseus Proteomics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 19 Jul 2023 Early research in Solid tumours in Japan (Parenteral), prior to July 2023 (Perseus Proteomics pipeline, July 2023)